Ligand discovery is a central step for the development of new pharmaceutical agents.
In close collaboration with ETH Zürich, we have developed breakthrough technologies for ligand discovery (e.g., DNAencoded chemical libraries) and in the field of chemical proteomics (e.g., in vivo biotinylation, MHC peptidome analysis).
The ability to discover ligands to pharmaceutical targets of interest can be used for many biomedical applications. Within the Philochem group, we mainly focus on ligand-based pharmacodelivery strategies.
The ability to characterize disease-associated targets and to perform MHC peptidome analysis paves the way to novel pharmaceutical applications.